Pharmacological Interaction between 3,4-Methylenedioxymethamphetamine (Ecstasy) and Paroxetine: Pharmacological Effects and Pharmacokinetics

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2007-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1124/jpet.107.129056PMID 17890444
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans

  2006cited by this paper
• Contribution of Cytochrome P450 2D6 to 3,4-Methylenedioxymethamphetamine Disposition in Humans

  2005influential reference
• MDMA induced dopamine release in vivo: role of endogenous serotonin

  2005cited by this paper
• MECHANISM-BASED INACTIVATION OF CYP2D6 BY METHYLENEDIOXYMETHAMPHETAMINE

  2004cited by this paper
• Paroxetine Inhibits Acute Effects of 3,4-Methylenedioxymethamphetamine on the Immune System in Humans

  2004cited by this paper
• Early Effects of Paroxetine on Serotonin Storage, Plasma Levels, and Urinary Excretion: A Randomized, Double-Blind, Placebo-Controlled Trial

  2004cited by this paper
• Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics

  2004cited by this paper
• Actions of amphetamine derivatives and cathinone at the noradrenaline transporter.

  2003cited by this paper
• The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)

  2003cited by this paper
• Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.

  2003cited by this paper
• P‐glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine and paramethoxyamphetamine

  2003cited by this paper
• Inhibition of P-Glycoprotein by Newer Antidepressants

  2003influential reference
• Construcción de un cuestionario para la Valoración de los Efectos Subjetivos de Sustancias con Potencial de Abuso (VESSPA): Evaluación del éxtasis

  2003cited by this paper
• Therapeutic and adverse actions of serotonin transporter substrates.

  2002cited by this paper
• Determination of MDMA and its metabolites in blood and urine by gas chromatography-mass spectrometry and analysis of enantiomers by capillary electrophoresis.

  2002cited by this paper
• The pharmacology of the acute hyperthermic response that follows administration of 3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) to rats

  2002cited by this paper
• 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics.

  2002cited by this paper
• Analgesic effect of intrathecally administered orexin‐A in the rat formalin test and in the rat hot plate test

  2002cited by this paper
• The mechanisms involved in the long‐lasting neuroprotective effect of fluoxetine against MDMA (‘ecstasy’)‐induced degeneration of 5‐HT nerve endings in rat brain

  2001cited by this paper
• Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain.

  2001cited by this paper
• Vascular actions of MDMA involve α1 and α2‐adrenoceptors in the anaesthetized rat

  2001cited by this paper
• Amphetamine‐type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin

  2001cited by this paper
• Vascular actions of MDMA involve alpha1 and alpha2-adrenoceptors in the anaesthetized rat.

  2001cited by this paper
• Pharmacology of MDMA in Humans

  2000cited by this paper
• Acute Psychological Effects of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”) are Attenuated by the Serotonin Uptake Inhibitor Citalopram

  2000cited by this paper
• The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in healthy volunteers

  2000influential reference
• Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.

  2000influential reference
• Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects.

  2000influential reference
• Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) are attenuated by the serotonin uptake inhibitor citalopram

  1999cited by this paper
• Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.

  1999cited by this paper
• Effects of "Ecstasy" blocked by serotonin reuptake inhibitors.

  1999cited by this paper
• Comparison of the Effects of Antidepressants and Their Metabolites on Reuptake of Biogenic Amines and on Receptor Binding

  1999cited by this paper
• Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice.

  1997cited by this paper
• Carrier‐Mediated Release of Serotonin by 3,4‐Methylenedioxymethamphetamine: Implications for Serotonin‐Dopamine Interactions

  1996cited by this paper
• Acute subjective responses to paroxetine in normal volunteers.

  1995cited by this paper
• The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6).

  1994cited by this paper
• Spanish version of the 49-item short form of the Addiction Research Center Inventory (ARCI).

  1994cited by this paper
• Reinforcing subjective effects of (+/-) 3,4-methylenedioxymethamphetamine ("ecstasy") may be separable from its neurotoxic actions: clinical evidence.

  1993cited by this paper
• Drug effects on distribution of [3H]3,4-methylenedioxymethamphetamine in mice.

  1993influential reference
• Alcohol and cocaine interactions in humans.

  1993cited by this paper
• Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites.

  1988influential reference
• Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine.

  1987cited by this paper

• Clinical pharmacology.

  2025cites this paper
• Ecstasy, molly, MDMA: What health practitioners need to know about this common recreational drug.

  2025cites this paper
• High Rates of Drug Use and Chemsex Among PrEP Users and People with HIV in Milan Highlight Need for Targeted Interventions

  2025cites this paper
• 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted psychotherapy: what the pharmacist needs to know

  2024influential citation
• MDMA pharmacokinetics: A population and physiologically based pharmacokinetics model‐informed analysis

  2024cites this paper
• Keeping the promise: a critique of the current state of microdosing research

  2024cites this paper
• Novel Benzofuran Derivatives Induce Monoamine Release and Substitute for the Discriminative Stimulus Effects of 3,4-Methylenedioxymethamphetamine

  2024cites this paper
• MDMA-assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy.

  2023cites this paper
• The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

  2023cites this paper
• MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults

  2022cites this paper
• Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes

  2022cites this paper
• Safety, tolerability, pharmacokinetics, and subjective effects of 50, 75, and 100 µg LSD in healthy participants within a novel intervention paradigm: A proof-of-concept study

  2022cites this paper
• Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database

  2022cites this paper
• Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects

  2022cites this paper
• Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review

  2022influential citation
• Psychedelic drugs for psychiatric disorders.

  2022cites this paper
• Impact of fluoxetine preexposure on MDMA-induced taste avoidance in male and female rats.

  2022cites this paper
• Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA/ecstasy and psilocybin) and major depressive episodes

  2022cites this paper
• Entactogens: How the Name for a Novel Class of Psychoactive Agents Originated

  2022cites this paper
• Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder

  2022cites this paper
• A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults

  2022cites this paper
• MDMA to Treat PTSD in Adults.

  2021cites this paper
• Ecstasy (3,4-methylenedioxymethamphetamine): cardiovascular effects and mechanisms.

  2021cites this paper
• Serotonin toxicity of serotonergic psychedelics

  2021influential citation
• Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database

  2021cites this paper
• Dosing Psychedelics and MDMA.

  2021cites this paper
• Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy

  2020cites this paper
• MDMA interactions with pharmaceuticals and drugs of abuse

  2020influential citation
• Cognitive consequences of 3,4-methylenedioxymethamphetamine use

  2020cites this paper
• Addiction of Hallucinogens, Dissociatives, Designer Drugs and “Legal Highs”: Update on Potential Therapeutic Use

  2020cites this paper
• RETRACTED ARTICLE: Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy

  2020cites this paper
• Serotonin and serotonin receptors in hallucinogen action

  2020cites this paper
• Adverse pharmacokinetic interactions between illicit substances and clinical drugs

  2019cites this paper
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

  2019cites this paper
• 2-Aminoindan and its ring-substituted derivatives interact with plasma membrane monoamine transporters and α2-adrenergic receptors

  2019cites this paper
• Pharmacologic chaos: severe hypotension from interactions of anesthetics, marijuana, amphetamines, and paroxetine.

  2019cites this paper
• Effects of MDMA on attention to positive social cues and pleasantness of affective touch

  2019cites this paper
• The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial

  2018cites this paper
• Pharmakologische Grundlagen: Mechanismen und Variabilität der Wirkung psychoaktiver Substanzen

  2018cites this paper
• Role of serotonin transporter and receptor gene variations in the acute effects of MDMA in healthy subjects.

  2018cites this paper
• Synthesis, analytical characterization, and monoamine transporter activity of the new psychoactive substance 4-methylphenmetrazine (4-MPM), with differentiation from its ortho- and meta- positional isomers.

  2018cites this paper
• Neuropharmacology of Synthetic Cathinones.

  2018cites this paper
• A translational perspective on neural circuits of fear extinction: Current promises and challenges

  2018cites this paper
• Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

  2018cites this paper
• Key interindividual determinants in MDMA pharmacodynamics

  2018cites this paper
• Safety pharmacology of acute MDMA administration in healthy subjects

  2017cites this paper
• Cardiovascular and temperature actions of cathinones

  2017cites this paper
• Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model

  2017cites this paper
• Effects of MDMA on the pupillary light reflex on its own and after pretreatment with reboxetine , duloxetine , clonidine , carvedilol , and doxazosin

  2017influential citation
• Neurochemical substrates of the rewarding effects of MDMA: implications for the development of pharmacotherapies to MDMA dependence

  2016cites this paper
• The effects of MDMA on socio-emotional processing: Does MDMA differ from other stimulants?

  2016cites this paper
• Contractile effects of 3,4-methylenedioxymethamphetamine on the human internal mammary artery.

  2016cites this paper
• Exploring MDMA: From Neurotoxicity to Therapeutic Potential

  2016cites this paper
• Treatment-refractory posttraumatic stress disorder (TRPTSD): a review and framework for the future.

  2016cites this paper
• Influence of Bupropion on the Effects of MDMA

  2015influential citation
• Interactions between Bupropion and 3,4-Methylenedioxymethamphetamine in Healthy Subjects

  2015influential citation
• Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart.

  2015cites this paper
• Acute Effects of Lysergic Acid Diethylamide in Healthy Subjects.

  2015cites this paper
• Inhibition of Cytochrome P450 Enzymes

  2015cites this paper
• Addiction to Hallucinogens, Dissociatives, Designer Drugs and “Legal Highs”

  2015cites this paper
• Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination.

  2014influential citation
• Pharmacology should be at the centre of all preclinical and clinical studies on new psychoactive substances (recreational drugs)

  2014cites this paper
• Effects of MDMA on body temperature in humans

  2014cites this paper
• Changes in serotonin transporter (5-HTT) gene expression in peripheral blood cells after MDMA intake

  2014cites this paper
• Ecstasy use and serotonin syndrome: a neglected danger to adolescents and young adults prescribed selective serotonin reuptake inhibitors

  2013cites this paper
• &agr;1-Adrenergic Receptors Contribute to the Acute Effects of 3,4-Methylenedioxymethamphetamine in Humans

  2013influential citation
• Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependency after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow-up study

  2013cites this paper
• 3,4-methylenedioxymethamphetamine (MDMA): current perspectives

  2013cites this paper
• Neurochemical substrates of MDMA reward: effects of the inhibition of serotonin reuptake on the acquisition and reinstatement of MDMA-induced CPP.

  2013cites this paper
• Study of the toxicological interactions between amphetamine designer drugs in the context of polydrug abuse

  2013cites this paper
• Ecstasy¿s Neurotoxicity: In Vitro Findings from Mitochondria to the Cell

  2013cites this paper
• The Deputy General Manager

  2013cites this paper
• 2. Ecstasy and the serotonin syndrome

  2013cites this paper
• A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD)

  2013cites this paper
• 3,4-methylenedioxymethamphetamine (MDMA): current perspectives

  2013cites this paper
• Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart

  2012cites this paper
• Pharmacokinetics and pharmacodynamics of 3,4-methylenedioxymethamphetamine (MDMA): interindividual differences due to polymorphisms and drug–drug interactions

  2012influential citation
• Lost in translation: preclinical studies on 3,4‐methylenedioxymethamphetamine provide information on mechanisms of action, but do not allow accurate prediction of adverse events in humans

  2012cites this paper
• Effects of the α2-Adrenergic Agonist Clonidine on the Pharmacodynamics and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Healthy Volunteers

  2012cites this paper
• Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study

  2012influential citation
• MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?

  2012cites this paper
• psychotherapy for treatment of resistant , chronic Post-Traumatic Stress Disorder ( PTSD ) A randomized , controlled pilot study of MDMA ( ± 3 , 4-Methylenedioxymethamphetamine )-assisted

  2012cites this paper
• MDMA enhances “mind reading” of positive emotions and impairs “mind reading” of negative emotions

  2012cites this paper
• Effects of MDMA alone and after pretreatment with reboxetine, duloxetine, clonidine, carvedilol, and doxazosin on pupillary light reflex

  2012influential citation
• Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT)

  2012cites this paper
• Drugs of Abuse

  2012cites this paper
• Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans

  2012cites this paper
• assisted psychotherapy : a Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects

  2012cites this paper
• MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans.

  2012cites this paper
• Behavioural and Neurochemical Consequences of MDMA Self-Administration in Rats

  2012cites this paper
• Methylenedioxymethamphetamine (Ecstasy, MDMA)

  2012cites this paper
• Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators.

  2012cites this paper
• Methylenedioxymethamphetamine (MDMA, ‘Ecstasy’): Neurodegeneration versus Neuromodulation

  2011cites this paper
• The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study

  2011cites this paper
• The Norepinephrine Transporter Inhibitor Reboxetine Reduces Stimulant Effects of MDMA (“Ecstasy”) in Humans

  2011cites this paper
• The effects of mirtazapine and fluoxetine on hyperthermia induced by 3,4-methylenedioxymethamphetamine (MDMA) in rats.

  2011cites this paper
• The safety and efficacy of 3 , 4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic , treatment-resistant posttraumatic stress disorder : the first randomized controlled pilot study

  2010cites this paper
• The cardiovascular and cardiac actions of ecstasy and its metabolites.

  2010cites this paper
• The role of monoamines in the changes in body temperature induced by 3,4‐methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives

  2010cites this paper
• Neurotoxicidade da "Ectasy" e dos seus metabolitos em células humanas dopaminérgicas SH-SY5Y

  2010cites this paper